Weight Watchers (WW) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Q1 2026 revenue was $168.3M, down 9.8% year-over-year, driven by a decline in behavioral subscriptions, partially offset by 32% growth in clinical subscriptions.
Net loss for Q1 2026 was $52M, reflecting higher depreciation and amortization from Fresh Start Accounting, and improved from a $72.6M loss in Q1 2025.
End-of-period subscribers totaled 2.7 million, with clinical subscribers up 46% year-over-year to 197,000 and Core+ behavioral tier up 6% to 537,000.
The company emerged from bankruptcy in June 2025, resulting in a new capital structure, Fresh Start Accounting, and a leadership transition in March 2026.
Board welcomed three new independent directors with expertise in transformation, healthcare, and GLP-1 market dynamics.
Financial highlights
Q1 2026 gross margin was 70.5%, with adjusted gross margin near record highs at 73.6% due to operational efficiencies.
Adjusted EBITDA for Q1 was a loss of $1.8M, with improvement expected in subsequent quarters; net loss margin was (30.9)%.
Q1 ARPU increased 13% year-over-year to $20.59, with clinical ARPU over 4x higher than behavioral ARPU.
Cash and cash equivalents at quarter-end were $121M.
Interest expense decreased to $11.5M from $27.6M year-over-year due to reduced debt post-bankruptcy.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $620M–$635M and adjusted EBITDA at $105M–$115M.
Clinical subscription revenue expected to be 25%-30% of 2026 revenue, up from 16% in 2025.
Modest adjusted gross margin declines expected in 2026 but to remain above 72%.
Cash generation expected for the remainder of 2026, with $45–$50M in interest costs and $5–$10M in cash taxes.
Management does not foresee needing additional liquidity in the next 12 months.
Latest events from Weight Watchers
- Clinical subscriber growth and higher ARPU drive 2026 outlook despite behavioral headwinds.WW
Q4 20251 May 2026 - Shareholders will vote on directors, auditor, and executive pay after a transformative restructuring.WW
Proxy filing30 Apr 2026 - Q2 2024 revenue fell 10.9% as clinical subscribers surged 120% and cost savings were targeted.WW
Q2 20242 Feb 2026 - Q3 revenue and subscribers fell, but clinical growth and cost actions supported margin gains.WW
Q3 202416 Jan 2026 - GLP-1 integration, financial restructuring, and targeted programs drive innovation and growth.WW
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference14 Jan 2026 - Clinical growth and cost cuts offset declines, but bankruptcy and high debt loom.WW
Q1 202514 Jan 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance and ESG focus.WW
Proxy Filing1 Dec 2025 - Q4 profit returned as clinical growth and cost actions offset revenue and subscriber declines.WW
Q4 20241 Dec 2025 - Debt cut by $1.15B, leverage below 3x, and operations continue during reorganization.WW
Investor Update25 Nov 2025